Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 17Thoracic 12Gynecologic 11Genitourinary 11Other solid neoplasm 9Head & Neck 7Breast 5Dermatologic 3Endocrine 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1NET 1Lymphoid 1CNS 1

Conditions

Recurrence 1Glioblastoma 1

Interventions

Temozolomide 610Radiotherapy 388Bevacizumab 254Magnetic Resonance Spectroscopy 203Cyclophosphamide 177Carboplatin 159Radiosurgery 146Etoposide 132Radiation 121Irinotecan 115Vincristine 114Cisplatin 102Filgrastim 100Specimen Handling 88Nivolumab 87pembrolizumab 82Lomustine 81Topotecan 73Surgical Procedures, Operative 73Doxorubicin 60Melphalan 59Carmustine 57sargramostim 53Radiotherapy, Intensity-Modulated 53Isotretinoin 53Peripheral Blood Stem Cell Transplantation 52Granulocyte Colony-Stimulating Factor 50Erlotinib Hydrochloride 50Everolimus 48Chemotherapy, Adjuvant 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × zimberelimab × CNS × Clear all
NCT04656535 2026-04-17

AB154 Combined With AB122 for Recurrent Glioblastoma

Yale University

Phase EARLY_PHASE1 Active not recruiting
46 enrolled
CNS

Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡